| Filed | Form | Description | |
|---|---|---|---|
| 3/28/25 | DEFA14A | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | → |
| 3/28/25 | DEF 14A | DEFINITIVE PROXY STATEMENT | → |
| 4/26/24 | DEFA14A | ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A | → |
| 4/26/24 | DEF 14A | ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A | → |
| 4/24/23 | DEFA14A | ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A | → |
| 4/24/23 | DEF 14A | ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 3/3/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| ↓ | |||
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need.